Companies Using AI to Identify Small Molecules to Treat Parkinson's

Iktos is working with Astrogen to use artificial intelligence (AI) to identify small molecules as candidates for the treatment of Parkinson's disease. Under the collaboration's terms, Iktos will apply its proprietary machine-learning algorithm to virtually "sketch"molecules directed against a defined target and shortlist candidates for preclinical studies, the companies reported in a press release. That target is not yet public. In turn, Astrogen will screen the candidates in the lab and inside living organisms, and it will guide the development process from preclinical to clinical stages. The companies will work together in the production and selection of molecules that show the most promise as a Parkinson's treatment.